Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on BriaCell Therapeutics and keeping the price target at $32.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emily Bodnar has given her Buy rating due to a combination of factors related to the promising clinical developments of BriaCell Therapeutics. The company’s Bria-IMT regimen has shown a significant survival benefit in patients with metastatic breast cancer (mBC), particularly in those who have undergone multiple prior lines of therapy. The recent Phase 2 study results indicated that 52% of patients surpassed a one-year survival milestone, which is notably higher than the current standard of care for this patient population.
Additionally, the Bria-OTS platform has demonstrated encouraging early results, with the first patient in the Phase 1/2a trial achieving a complete resolution of lung metastasis after six months of treatment. This provides early proof of concept for the platform’s efficacy as a personalized treatment option. The expansion of clinical sites for the Phase 3 trial and the potential for interim overall survival data by early 2026 further support the positive outlook for BriaCell’s therapeutic offerings, justifying the Buy rating.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Olema Pharmaceuticals, and NovoCure. According to TipRanks, Bodnar has an average return of -6.2% and a 31.37% success rate on recommended stocks.